Do People With Tophaceous Gout Require More Allopurinol for Good Clinical Outcomes? Analysis of 2 Randomized Controlled Trials of Allopurinol Dose Escalation.
Lisa K Stamp, Anne Horne, Jill Drake et al.
✦ AI-curated · Sources linked
In 30 seconds
This analysis of individual participant data from two randomized allopurinol dose-escalation trials compared outcomes in people with gout with and without baseline tophi. Both trials used treat-to-target dosing, aiming for serum urate below 0.36 mmol/L. At 12 months, target serum urate was achieved by 70.3% of participants with tophi and 73.6% without tophi (P = 0.76). The proportion without gout flares in the month before month 12 was also not significantly different: 71.4% versus 79.7% (P = 0.27).
Key findings
- At month 12, 70.3% with tophi and 73.6% without tophi reached target serum urate (P = 0.76).
- Absence of gout flares in the month before month 12 was reported by 71.4% with tophi and 79.7% without tophi (P = 0.27).
- Tophi were present in 33% of participants.
Why it matters
The findings suggest that, within a treat-to-target approach, people with tophaceous gout can achieve urate-lowering and flare outcomes comparable to those without tophi. This helps contextualize the assumption that tophi necessarily require greater allopurinol dosing to obtain good clinical outcomes, while emphasizing serum urate targets and observed outcomes rather than tophus status alone.
What to keep in mind
The analysis reports outcomes over 1 year and compares subgroups defined by baseline tophi; it does not establish that tophi status has no effect beyond this follow-up or under other treatment strategies.